GlassScriptPhysician profile
Brent O Davis
NPI 1871588012
$10,837.77
in general payments reported to CMS, 2019-2025
25 companies · $4,258 in 2025
The $4,258 reported for 2025 was more than what 81% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,392 · 2020: $163 · 2021: $639 · 2022: $429 · 2023: $656 · 2024: $1,300 · 2025: $4,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,088 · Travel and Lodging: $2,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,088.47 |
| Travel and Lodging | $2,125.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $3,463.49 | 2022-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbott Laboratories | $2,802.73 | 2019-2025 | Triclip, Dragonfly Opstar, Aveir |
| Cardiovascular Systems INC. | $1,669.56 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $848.40 | 2019-2025 | |
| Medtronic, INC. | $718.63 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Viance |
| Shockwave Medical, INC | $465.22 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Cvrx, INC. | $142.53 | 2022-2025 | Barostim Neo System |
| Inari Medical, INC. | $136.05 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $116.89 | 2019-2025 | Lifevest |
| Amgen INC. | $115.09 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $67.83 | 2019-2022 | |
| Amarin Pharma, INC. | $43.77 | 2019-2022 | |
| Pfizer INC. | $37.12 | 2023-2024 | |
| Boston Scientific Corporation | $33.63 | 2019 | |
| Abiomed | $31.06 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $24.85 | 2024 | |
| Siemens Medical Solutions USA, INC. | $24.68 | 2025 | |
| Cmp Pharma, INC. | $24.61 | 2021-2023 | Norliqva, Tadliq, Carospir |
| Merck Sharp & Dohme LLC | $19.87 | 2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.66 | 2023 | Jardiance |
| Medtronic Vascular, INC. | $13.29 | 2020 | |
| Novo Nordisk INC | $13.20 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.61 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.